Revance Therapeutics

^{Priced, Nasdaq: RVNC}

Clinical-stage biotech developing a non-injectable formulation of botulinum toxin.

Industry: Health Care

First Day Return: +67.8%

RVNC

Clinical-stage biotech developing a non-injectable formulation of botulinum toxin.

IPO News for Revance Therapeutics

Botox for the masses: Evolus files for a $75 million IPO 01/09/18
Botox biotech Anterios postpones $51 million IPO 05/15/15
Botox biotech Anterios files for a $58 million IPO 03/31/15

IPO Data
IPO Date	02/05/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$96
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.revance.com
Headquarters	Newark, CA, United States
Founded	1999
Employees at IPO	64

IPO News for Revance Therapeutics

Botox for the masses: Evolus files for a $75 million IPO 01/09/18
Botox biotech Anterios postpones $51 million IPO 05/15/15
Botox biotech Anterios files for a $58 million IPO 03/31/15

Revance Therapeutics (RVNC) Performance